Lupin has received approval from Drugs Controller General (India) (DCGI) to conduct Phase-II clinical trials for the molecule LL-42 18 (Desoside-P). The company received permission to continue Phase-II clinical trials on the compound, LL-42 18, after DCGI found the clinical Phase-I data of the molecule to be satisfactory.Lupin is planning to begin clinical trials at 5-6 centres immediately, according to a release issued by the company to the BSE today."We are delighted that our Phase-I data has been found to be satisfactory for us to proceed with further clinical trials. We are very excited with taking the molecule forward, and look forward to meeting this otherwise unmet market need," chairman Desh Bandhu Gupta said.LL-4218, a pure molecule, is obtained from a plant source and is intended for the treatment of chronic stable plaque type psoriasis. This molecule's novel mechanism of action leads to marked psoriatic lesion improvement without any toxic effects.
